Glucose Sensors and Insulin Pumps: Prospects for an Artificial Pancreas

2009 ◽  
pp. 77-91
Author(s):  
Martin Press
2021 ◽  
Vol 24 (2) ◽  
pp. 86
Author(s):  
Papa, G.

The monitoring and treatment of type 1 diabetes (T1D) are undergoing profound changes today. Notable steps include the improvement and widespread adoption of glucose sensors which are now extremely reliable and furthermore are used with insulin pumps in an integrated manner. Over the last 2 to 3 years these systems have evolved rapidly with the development and use of algorithms which permit the autonomous regulation of basal insulin. Correct control and administration of basal insulin is often the greatest stumbling block in multiple daily injection therapy as basal insulins cannot replicate the physiological rhythms of basal insulin secretion. Hypoglycemia is another critical point in standard insulin pen therapy as it does not permit dosage modulation in the same way as with an insulin pump. In this article we cover the fundamental steps in this revolution of insulin therapy which promises, in the not too distant future, the ultimate achievement of the artificial pancreas and thus the complete closure of the loop. All those working in diabetes care must be adequately trained and familiar with this technology as it should no longer be considered a niche treatment reserved for carefully selected patients and managed in only a few centers of excellence. In order to choose the best treatment, tailored to each individual patient’s needs, medical staff involved in the treatment of T1D require a thorough knowledge of standalone glucose sensors, insulin pumps and integrated systems with control algorithms.Once the critical issues (costs, psychological aspects, system management difficulties, alarm fatigue, etc.) still related to their use have been resolved, new Hybrid Closed Loop and Advanced Hybrid Closed Loop systems could become the new standard in the treatment of T1D. KEY WORDS type 1 Diabetes; insulin pump; decision-making algorithms; integrated system.


Author(s):  
Emmanuel Andrès ◽  
Nathalie Jeandidier ◽  
Samy Talha ◽  
Abrar-Ahmad Zulfiqar ◽  
Laurent Meyer ◽  
...  

In recent years, several technological innovations have become part of the daily lives of patients suffered from chronic diseases. It is the case for diabetes mellitus and chronic heart failure with noninvasive glucose sensors, intelligent insulin pumps, artificial pancreas, telemedicine, and artificial intelligence for an optimal management. A review of the literature dedicated to these technologies and devices supports the efficacy of the latter. Mainly, these technologies have shown a beneficial effect on diabetes or chronic heart failure management with mainly improvement for these two diseases of patient ownership of the disease; patient adherence to therapeutic and hygiene-dietary measures; the management of comorbidities (hypertension, weight, dyslipidemia); and at least, good patient receptivity and accountability. Especially, the emergence of these technologies in the daily lives of these patients suffered from chronic disease has led to an improvement of the quality of life for patients. Nevertheless, the magnitude of its effects remains to date debatable or to be consolidated, especially with the variation in patients’ characteristics and methods of experimentation and in terms of medical and economic objectives.


1999 ◽  
Vol 56 (4-5) ◽  
pp. 190-194
Author(s):  
E.Christopher Ellison

Author(s):  
Ulrik Ahrensbøll‐Friis ◽  
Anne Birgitte Simonsen ◽  
Claus Zachariae ◽  
Jacob P. Thyssen ◽  
Jeanne D. Johansen

Sign in / Sign up

Export Citation Format

Share Document